Stockreport

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union [Yahoo! Finance]

Insmed, Inc.  (INSM) 
Last insmed, inc. earnings: 4/30 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation — — BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pat [Read more]